Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer


Rapamycin analogs temsirolimus and everolimus have been approved for the treatment of advanced renal cancer and are being tested in a wide spectrum of human tumors. However, objective response rates with rapalogs in clinical trials were modest and variable. Identification of biomarkers capable of predicting response to rapalogs is of increasing interest. We… (More)
DOI: 10.1007/s00109-010-0635-0


7 Figures and Tables